A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever
ConclusionsCollectively, the results from this randomized phase 1 clinical trial indicate that Typhax is safe, well tolerated, and immunogenic. After a single dose, Typhax at the 2.5 and 10 μg dose levels elicited comparable anti-Vi IgG titers and seroconversion rates as a single dose of Typhim Vi (25 μg dose). A second dose of Typhax at Day 28 did not elicit a booster response. Trial registrationClinicalTrials.gov NCT03926455.
Publication date: Available online 3 June 2020Source: Carbohydrate PolymersAuthor(s): Zhenguang Liu, Lin Yu, Pengfei Gu, Ruonan Bo, Adelijiang Wusiman, Jiaguo Liu, Yuanlaing Hu, Deyun Wang
Publication date: Available online 3 June 2020Source: Pharmacology Biochemistry and BehaviorAuthor(s): Yasunori Haranishi, Koji Hara, Tadanori Terada
Authors: Ferella A, Aguirreburualde MSP, Sammarruco A, Parreño V, Santos MJD, Mozgovoj M Abstract Bovine respiratory syncytial virus (BRSV) is one of the most relevant agents responsible for respiratory disease in cattle from both dairy and beef farms. BRSV is spread by horizontal contact causing a constant presence of seropositive animals that favors viral circulation throughout the year. Moreover, reinfections with BRSV are frequent between animals regardless of their age as BRSV does not confer long-lasting protective immunity. Several studies have demonstrated the circulation of BRSV in cattle from diffe...
CONCLUSIONS: Immunization Information System is an essential technological innovation for the management of immunization actions. However, the production of timely records and the use of information are still challenges. Investments in training are required to ensure System's management and operationalization activities. PMID: 32490998 [PubMed - in process]
Typhoid fever is a systemic disease caused by Salmonella enterica serovar Typhi (S. Typhi), clinically characterized in its most severe phase due to fever, fatigue, abdominal pain, diarrhea, and constipation or diarrhea. Mortality rates for typhoid fever remain high in population in Asia, especially in the Indian subcontinent (Crump and Mintz, 2010). Typhoid fever remains endemic in regions of limited access to sanitary conditions, and the transmission occurs through consumption of water and food contaminated by feces or urine of infected people (Parry and Threlfall, 2008; Sharma et al., 2016; Wong et al., 2016).
Conclusions: Typhoid fever was frequent among immigrants to endemic areas. Travelers returning from endemic areas with suspected typhoid fever should be treated empirically with third-generation cephalosporin after obtaining appropriate cultures. Moreover, preventive measurements such as education on food and water hygiene, and effective vaccination of travelers should be practiced widely among travelers to endemic areas to reduce morbidity and mortality. PMID: 30410688 [PubMed]
LITFL • Life in the Fast Lane Medical Blog LITFL • Life in the Fast Lane Medical Blog - Emergency medicine and critical care medical education blog aka Tropical Travel Trouble 010 Peer Reviewer: Dr Jennifer Ho, ID physician QLD, Australia You are an ED doc working in Perth over schoolies week. An 18 yo man comes into ED complaining of fever, rash a “cracking headache” and body aches. He has just hopped off the plane from Bali where he spent the last 2 weeks partying, boozing and running amok. He got bitten by “loads” of mosquitoes because he forgot to take insect repellent. On e...
CONCLUSIONS: The licensed Ty21a and Vi polysaccharide vaccines are efficacious in adults and children older than two years in endemic countries. The Vi-rEPA vaccine is just as efficacious, although data is only available for children. The new Vi-TT vaccine (PedaTyph) requires further evaluation to determine if it provides protection against typhoid fever. At the time of writing, there were only efficacy data from a human challenge setting in adults on the Vi-TT vaccine (Tybar), which clearly justify the ongoing field trials to evaluate vaccine efficacy. PMID: 29851031 [PubMed - as supplied by publisher]
Conclusion: Typhoid perforation continues to cause morbidity and mortality in children in developing countries. To stem this endemic disease, community health education and improved living conditions are required.
CONCLUSIONS: A single dose of typhoid Vi polysaccharide vaccine, Typhim Vi(®), demonstrated good safety and immunogenicity profile in a Japanese population. PMID: 26518404 [PubMed - as supplied by publisher]